Study Published in Cancer Research Shows Anticancer Activity of Xcytrin
Pharmacyclics has announced that Cancer Research, the journal of the American Association for Cancer Research (AACR), published a study that further characterizes the mechanism of action of Xcytrin injection and provides better understanding of the drug's unique anticancer properties.
The study was conducted by scientists from the Institute for Genetic Medicine at the University of Southern California and the Department of Radiation Oncology at the University of Pennsylvania in collaboration with Pharmacyclics.
To gain a better understanding of the mechanism of action of Xcytrin, researchers conducted a series of gene expression profiling analyses and biochemical studies on human lung, prostate and lymphoma cancer cell cultures treated with Xcytrin.
In this study, researchers showed that the enzyme activity of thioredoxin reductase was inhibited in cancer cells treated with Xcytrin. The authors indicate that Xcytrin may have multiple targets for its activity within the cancer cell, which result in oxidative stress and impairment of metabolism.